These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11030037)

  • 21. Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities.
    Andiné P; Rönnbäck L; Järvholm B
    Acta Psychiatr Scand; 1997 Jul; 96(1):82-3. PubMed ID: 9259230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
    DeVane CL
    Cell Mol Neurobiol; 1999 Aug; 19(4):443-66. PubMed ID: 10379420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous vasculitis during selective serotonin reuptake inhibitor therapy.
    Flores-Suárez LF; Vega-Memije ME; Chanussot-Deprez C
    Am J Med; 2006 Oct; 119(10):e1-3. PubMed ID: 17000205
    [No Abstract]   [Full Text] [Related]  

  • 24. Selective serotonin re-uptake inhibitors (SSRIs) and alopecia areata.
    Ruiz-Doblado S; Carrizosa A; García-Hernández MJ; Rodríguez-Pichardo A
    Int J Dermatol; 1999 Oct; 38(10):798-9. PubMed ID: 10561061
    [No Abstract]   [Full Text] [Related]  

  • 25. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of new antidepressants: focus on duloxetine and escitalopram.
    Huffman JC; Perlis RH
    Harv Rev Psychiatry; 2003; 11(1):30-6. PubMed ID: 12866739
    [No Abstract]   [Full Text] [Related]  

  • 27. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
    Stahl SM
    J Clin Psychiatry; 1998 Dec; 59(12):642-3. PubMed ID: 9921697
    [No Abstract]   [Full Text] [Related]  

  • 28. Risks with citalopram in perspective.
    Isacsson G; Bergman U
    Lancet; 1996 Oct; 348(9033):1033. PubMed ID: 8855882
    [No Abstract]   [Full Text] [Related]  

  • 29. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
    J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
    Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
    Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amisulpride augmentation after the failure of citalopram for depression: a case report.
    Carvalho AF; Nunes-Neto PR; Cavalcante JL; Oliveira Lima MC
    J Clin Pharm Ther; 2007 Feb; 32(1):97-9. PubMed ID: 17286793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis.
    Tan S; Huang X; Ding L; Hong H
    Eur Neurol; 2015; 74(3-4):188-201. PubMed ID: 26559658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PharmGKB summary: citalopram pharmacokinetics pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2011 Nov; 21(11):769-72. PubMed ID: 21546862
    [No Abstract]   [Full Text] [Related]  

  • 34. Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxymethamphetamine?
    Lauerma H; Wuorela M; Halme M
    Biol Psychiatry; 1998 Jun; 43(12):929. PubMed ID: 9627751
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The precipitation of mania by citalopram in a patient with interferon-induced depression.
    Beckwith AR
    Psychosomatics; 2008; 49(4):362-3. PubMed ID: 18621943
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
    Lin YT; Lu TS; Hansen RA; Wang CC
    Clin Ther; 2019 Jun; 41(6):1128-1138.e8. PubMed ID: 31178037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychopharmacological approach with the usage of selective serotonin reuptake inhibitors in functional dyspepsia treatment].
    Korendovych IV; Svintsits'kyĭ AS; Revenok KM; Maliarov SO
    Lik Sprava; 2014 Nov; (11):58-64. PubMed ID: 25528834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Galactorrhoea and the use of selective serotonin reuptake inhibitors].
    Wessels-van Middendorp AM; Timmerman L
    Tijdschr Psychiatr; 2006; 48(3):229-34. PubMed ID: 16956087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
    Spigset O; Adielsson G
    Int Clin Psychopharmacol; 1997 Jan; 12(1):61-3. PubMed ID: 9179637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.